Repligen (NASDAQ:RGEN) Updates FY24 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share guidance of $1.42-1.49 for the period, compared to the consensus earnings per share estimate of $1.46. The company issued revenue guidance of $620-650 million, compared to the consensus revenue estimate of $635.70 million.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Stifel Nicolaus lifted their price target on shares of Repligen from $165.00 to $207.00 and gave the company a buy rating in a report on Thursday, February 22nd. KeyCorp lifted their price target on shares of Repligen from $210.00 to $220.00 and gave the company an overweight rating in a report on Thursday, February 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $196.70.

Repligen Stock Performance

Repligen stock opened at $164.20 on Wednesday. The company’s 50-day moving average price is $182.66 and its 200-day moving average price is $173.96. Repligen has a twelve month low of $110.45 and a twelve month high of $211.13. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26. The company has a market cap of $9.17 billion, a PE ratio of 228.06, a price-to-earnings-growth ratio of 5.44 and a beta of 1.02.

Repligen (NASDAQ:RGEN) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The firm had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. During the same period in the previous year, the firm posted $0.68 EPS. The business’s quarterly revenue was down 16.6% on a year-over-year basis. On average, equities research analysts forecast that Repligen will post 1.46 EPS for the current fiscal year.

Insider Transactions at Repligen

In related news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the transaction, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock worth $5,039,532 in the last three months. Insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.